(NP (-LRB- -LCB-) (NP (NNS Changes)) (PP (IN in) (NP (NP (JJ leucocytic) (NN estrogen) (NN receptor) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN gynecomastia))))))) (-RRB- -RCB-))
(S (NP-SBJ-62 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ human) (JJ peripheral) (NNS leucocytes)) (PP (IN in) (NP (NP (CD 13) (NNS men)) (PP (IN with) (NP (NNS gynecomastia)))))))))) (VP (VBD were) (VP (VBN measured) (NP (-NONE- *-62)) (PP (IN by) (NP-LGS (NN radioligand) (NN binding) (NN method))))) (. .))
(S (NP-SBJ-63 (DT The) (NNS results)) (VP (VBD were) (VP (VBN compared) (NP (-NONE- *-63)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (CD 13) (ADJP (NN sex-) (CC and) (JJ age-matched)) (JJ healthy) (NNS subjects))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ-64 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN ER)) (PP (IN in) (NP (NNS leucocytes)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN increased) (NP (-NONE- *-64)) (PP (IN in) (NP (NN gynecomastia))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NP (NN Rs)) (PP (IN of) (NP (NNS leucocytes)))) (VP (VBD were) (NP-PRD (QP (CD 1054) (CC (- +)) (CD 254)) (NN (cell sites))))) (-RRB- -RRB-)))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP (NN increase)) (PP (IN of) (NP (NN ER) (NNS levels)))) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN gynecomastia))))))))) (. .))
